Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the zig and the zag, from weakness to strength in four (4) hours

March 25, 2021 6:28pm

As volatility facilitates an upside bounce but, are these buyers’ term oriented or just algorithm driven – don’t guess, it’s the electronics

Pre-open indication results: 5 HITs and 4 MISS

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed UP +199.42 points (+0.62%); the S&P closed UP +20.38 points (+0.52%) while the Nasdaq closed UP +15.79 points (+0.12%)

Henry’omics:

Indexes staged a late-day comeback on Thursday, rebounding from a two-day losing streak while the cell and gene therapy sector popped after a lousy session start.

Thursday’s moves pared the major averages’ week-to-date losses, as the S&P 500 and the Dow are down -0.1% each after hitting their record highs last week while the Nasdaq underperformed with a -1.8% loss this week.

The market experienced weakness earlier in the day as Fed Chair Powell hinted at one day starting to remove the stimulus that has boosted the market during the pandemic.

Data Docket: The Labor Department said first-time claims for unemployment insurance totaled 684,000 for the week ended March 20, lower than an estimate of 735,000.

RegMed Investors’ (RMi) pre-open: “bottom-fishing in a small pond and maybe watching a knife fall. The question will be, which sector equities are ready for a bounce, are undervalued, having sustainable pricing based on wandering investor behavior or fundamental changes?” … https://www.regmedinvestors.com/articles/11831

Pre-open indication results: 5 HITs < Biostage (BSTG -$0.00 with 39 shares), bluebird bio (BLUE +$1.33), Homology Medicine (FIXX +$0.14), Sangamo Therapeutics (SGMO +$0.71), Editas Medicine (EDIT +$1.19) and 4 MISS < CRISPR Therapeutics (CRSP -$0.95), MiMedx (MDXG -$0.27), Verastem (VSTM +$0.03), Vericel (VCEL +$2.79)

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

Thursday opened negative at 6/27, 1 flat and 1 acquired, strayed positive at the mid-day to 18/15 1 flat and 1 acquired, closing positive at 22/11, 1 flat and 1 acquired;

There are clear winners and losers

Jumping with share pricing momentum:

Vericel (VCEL), Intellia Therapeutics (NTLA), bluebird bio (BLUE), Editas Medicine (EDIT), Cellectis SA (CLLS) to name 5 of the 11 inclining of the 35 covered

Hammered in today’s market:

Fate Therapeutics (FATE), ReNeuron (RENE.L), BioLife Solutions (BLFS), CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) to name 5 of the 11 declining of the 35 covered

Key metrics:

Sector volume had LOW with 7 of the 22-upside having higher than the 3-month average volume with the volume of 6 of 11-downside having higher than the 3-month average volume;

Thursday’s percentage (%) of the 22-upside was +0.03% (RGNX) to +10.32% (ADVM) while the 11-downside ranges from -0.12% (RARE) to -6.44% (BCLI);

Thursday’s (10 of 22) incline

Vericel (VCEL +$2.79 after Wednesday’s -$4.05);
Intellia Therapeutics (NTLA +$2.25 after Wednesday’s -$4.00, Tuesday’s -$3.17 and Monday’s +$2.68);
bluebird bio (BLUE =$1.33);
Editas Medicine (EDIT +$1.19 after Wednesday’s -$5.09, Tuesday’s -$2.40 and Monday’s +$3.48);
Cellectis SA (CLLS +$1.04);
Adverum Biotechnologies (ADVM +$0.95);
Sangamo Therapeutics (SGMO +$0.71);
Alnylam Pharmaceuticals (+$0.61 after Wednesday’s -$4.03, Tuesday’s -$5.59 and Monday’s -$0.01)
Solid Biosciences (SLDB +$0.46 after offering close);
Global Blood Therapeutics (GBT +$0.37);

Thursday’s (11 of 11) decliners:

Fate Therapeutics (FATE -$3.46 after Wednesday’s -$5.21, Tuesday’s -$4.73 and Monday’s +$1.63);
ReNeuron (RENE.L -$1.50 after Wednesday’s -$3.00, Tuesday’s -$3.00 and Monday’s -$1.00);
BioLife Solutions (BLFS -$1.25 after Wednesday’s -$3.02, Tuesday’s +$3.41 after Q4 earnings’ loss, merger and Monday’s -$0.19);
CRISPR Therapeutics (CRSP -$0.95 after Wednesday’s -$10.94, Tuesday’s -$6.51 and Monday’s +$3.39);
Ionis Pharmaceuticals (IONS -$0.77);
Chinook Therapeutics (KDNY -$0.74);
Mesoblast (MESO -$0.39);
MiMedx (MDXG -$0.27);
Brainstorm Cell Therapeutics (BCLI -$0.26 after Wednesday’s +$0.02 and news of positive Topline Data in P2 Study Evaluating NurOwn® as a Treatment for Progressive MS);
Ultragenyx (RARE -$0.13 after Wednesday’s -$6.05, Tuesday’s -$6.57 and Monday’s -$1.16);
Caladrius Bioscience (CLBS -$0.04);

Closing: 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)

Sentiment and COVID-19 infections:

Sentiment was on display in “our’ universe of cell and gene therapy equities – mainly because they appeared oversold versus valuation conflicted.
And I got my shot - 2nd Pfizer (PFE) innoculation

Infection cases <Million>: never to forget …

Thursday 30.05 M cases,
Thursday’s death rate totaled 545,941 <Johns Hopkins University>

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Thursday, the IBB closed up +1.02% and XBI closed up +2.88%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Thursday was down -1.39 points or -6.56% at 19.81

Upside volume: low

Thursday: 7 out of the 22-upside had higher than the 3-month average volume;

Downside volume: low

Thursday: 6 out of the 11-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

Thursday’s percentage (%) of the 22-upside was +0.03% (RGNX) to +10.32% (ADVM) while the 11-downside ranges from -0.12% (RARE) to -6.44% (BCLI);

March, the 3^rd month of Q1/21:

Thursday closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired

Wednesday closed negative with 1 advancer, 33 decliners and 1 acquired

Tuesday closed negative with 3 advancers, 31 decliners and 1 acquired

Monday (3/22) closed negative with 16 advancers, 18 decliners and 1 acquired

The BOTTOM LINE: As I had stated, follow the bouncing stock pricing in our universe of cell and gene therapy sector which has seesawed this week (so far) following a two and a half (2.5) month-long rotation which has skewered my outlook for growth, leaving a haphazard path traveled and to be traversed!

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run as volatility rules!

“Again, my time horizon for HOLDING an equity is last Friday to the coming Friday” – think about that and check the Advance/Decline (A/D line) to VALIDATE my thesis.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.